ATE415962T1 - Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs - Google Patents

Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs

Info

Publication number
ATE415962T1
ATE415962T1 AT01920974T AT01920974T ATE415962T1 AT E415962 T1 ATE415962 T1 AT E415962T1 AT 01920974 T AT01920974 T AT 01920974T AT 01920974 T AT01920974 T AT 01920974T AT E415962 T1 ATE415962 T1 AT E415962T1
Authority
AT
Austria
Prior art keywords
asiaticoside
asiatic acid
treat cancer
cancer
acid
Prior art date
Application number
AT01920974T
Other languages
English (en)
Inventor
Se-Kyung Oh
Chokyun Rha
Kadir Azizol Abdul
Lean Teik Ng
Original Assignee
Government Of Malaysia
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of Malaysia, Massachusetts Inst Technology filed Critical Government Of Malaysia
Application granted granted Critical
Publication of ATE415962T1 publication Critical patent/ATE415962T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT01920974T 2000-08-29 2001-02-14 Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs ATE415962T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI20003987A MY138883A (en) 2000-08-29 2000-08-29 Use of asiatic acid for treatment of cencer

Publications (1)

Publication Number Publication Date
ATE415962T1 true ATE415962T1 (de) 2008-12-15

Family

ID=19749475

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01920974T ATE415962T1 (de) 2000-08-29 2001-02-14 Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs

Country Status (9)

Country Link
US (1) US20040097463A1 (de)
EP (1) EP1313462B1 (de)
JP (2) JP2004507496A (de)
AT (1) ATE415962T1 (de)
AU (1) AU2001247968A1 (de)
DE (1) DE60136826D1 (de)
DK (1) DK1313462T3 (de)
MY (1) MY138883A (de)
WO (1) WO2002017904A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144312A1 (en) * 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
KR100571886B1 (ko) 2004-02-23 2006-04-17 학교법인 영남학원 아시아틱산을 포함하는 피부암 예방 또는 치료용 조성물
ATE514434T1 (de) * 2004-02-25 2011-07-15 Dana Farber Cancer Inst Inc Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum
WO2006012015A2 (en) * 2004-06-29 2006-02-02 Oregon Health And Science University Methods and compositions for nerve regeneration
US20070010459A1 (en) * 2005-01-14 2007-01-11 Ying Liu Application of asiatic acid and its derivatives to treat pulmonary fibrosis
US20090018146A1 (en) * 2005-01-27 2009-01-15 Research Development Corporation Combination Therapy with Triterpenoid Compounds and Proteasome Inhibitors
ES2535088T3 (es) * 2008-01-11 2015-05-05 Shanghai Institute Of Pharmaceutical Industry Formulaciones terapéuticas basadas en ácido asiático y sales seleccionadas del mismo
EP3062106B1 (de) 2008-04-16 2020-11-11 The Johns Hopkins University Verfahren zur bestimmung von varianten des andorgen rezeptors in prostatakrebs
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
CN102725133B (zh) 2009-12-21 2016-03-23 倍耐力轮胎股份公司 控制制备轮胎设备生产周期的方法、构造轮胎的工艺及设备
EP2582376B1 (de) * 2010-06-10 2018-05-23 Indus Biotech Private Limited Verfahren zur herstellung einer hochreinen asiaticosidzusammensetzung aus centella asiatica und anwendungsverfahren dafür
ES2647566T3 (es) * 2011-01-31 2017-12-22 Lucolas-M.D. Ltd. Combinaciones de inhibidores de aromatasa y antioxidantes
US20140194368A1 (en) * 2013-01-04 2014-07-10 Beech Tree Labs, Inc. Method of Treating Cancer by Administration of Low Levels of Heat Shock Protein 70 (HSP70)
WO2014153215A1 (en) 2013-03-14 2014-09-25 University Of Maryland,Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
KR20240119156A (ko) * 2013-05-03 2024-08-06 셀렉타 바이오사이언시즈, 인크. 제i형 및 제iv형 과민성을 감소시키기 위한 관용유발 합성 나노담체의 국부, 병용 투여
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
EP3146081B1 (de) 2014-05-19 2020-10-28 The Johns Hopkins University Verfahren zur identifizierung von androgenrezeptorspleissvarianten bei patienten mit kastrationsresistentem prostatakrebs
CA2959336A1 (en) * 2014-08-25 2016-03-03 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
EP3124047A1 (de) * 2015-07-28 2017-02-01 Merz Pharma GmbH & Co. KGaA Pentacyclische triterpene zur injektionslipolyse
US20180228815A1 (en) * 2016-11-09 2018-08-16 The Chinese University Of Hong Kong Naringenin and asiatic acid combination treatment of cancers
EP3592389B1 (de) 2017-03-11 2025-05-07 Cartesian Therapeutics, Inc. Verfahren und zusammensetzungen in zusammenhang mit einer kombinierten behandlung mit entzündungshemmenden mitteln und synthetischen nanoträgern mit einem immunsuppressivum
WO2019200585A1 (en) * 2018-04-19 2019-10-24 The Chinese University Of Hong Kong Naringenin and asiatic acid combination treatment of cancers
CN113039204A (zh) * 2018-10-18 2021-06-25 中国抗体制药有限公司 治疗类风湿性关节炎的方法
CN109528735B (zh) * 2019-01-30 2021-03-12 中国药科大学 积雪草苷在制备治疗皮肤癌药物中的新用途
CN110200981A (zh) * 2019-06-06 2019-09-06 中国药科大学 五环三萜皂苷的医药用途及其药物组合物
WO2022040341A1 (en) * 2020-08-20 2022-02-24 The Board Of Trustees Of The Leland Stanford Junior University Abscopal therapy for cancer
US20250275978A1 (en) * 2024-03-04 2025-09-04 Cardiff Oncology, Inc. Use of onvansertib as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB923414A (en) * 1960-04-13 1963-04-10 Laroche Navarron Lab Therapeutic compositions comprising asiatic and arjunolic acids
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
EP0383171A3 (de) * 1989-02-11 1991-07-24 Hoechst Aktiengesellschaft 2,3,23-Trihydroxy-urs-12-en Derivate zur Behandlung von Kognitiven Störungen
FR2714598B1 (fr) * 1993-12-30 1996-02-09 Oreal Composition amincissante à deux types de liposomes pour traitement topique, son utilisation.
JPH08133952A (ja) * 1994-11-07 1996-05-28 Shiseido Co Ltd 皮膚外用剤
CN1075802C (zh) * 1996-11-27 2001-12-05 东国制药株式会社 A环被修饰的积雪草酸衍生物
IT1288257B1 (it) * 1996-11-29 1998-09-11 Paoli Ambrosi Gianfranco De Composizione per uso cosmetico,farmaceutico o dietetico a base di un aminozucchero e/o di un acido poliidrossilico
FR2763336B1 (fr) * 1997-05-14 1999-08-06 Lvmh Rech Esters de tocopherol et leurs utilisations en cosmetique et pharmacie
ZA200700367B (en) * 2004-06-14 2008-07-30 Zoser B Salama Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody

Also Published As

Publication number Publication date
JP2004507496A (ja) 2004-03-11
MY138883A (en) 2009-08-28
JP2012092110A (ja) 2012-05-17
EP1313462A1 (de) 2003-05-28
DK1313462T3 (da) 2009-03-30
AU2001247968A1 (en) 2002-03-13
US20040097463A1 (en) 2004-05-20
DE60136826D1 (de) 2009-01-15
EP1313462B1 (de) 2008-12-03
WO2002017904A1 (en) 2002-03-07
JP5421340B2 (ja) 2014-02-19

Similar Documents

Publication Publication Date Title
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
PT1153024E (pt) 2-amino-6-anilino-purinas e sua utilizacao como medicamentos
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
ATE177421T1 (de) Wasserlösliches nimesulid-salz, sowie dessen verwendung zur behandlung von entzündungen
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE411016T1 (de) Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
DE602004016950D1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE60027127D1 (de) Verwendung von Polyaminosäurederivaten zur Behandlung von Seborrhoe und verwandten Hautstörungen
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
DE50111407D1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
ATE314066T1 (de) Verwendung von buprenorphin zur therapie der harninkontinenz
ATE460168T1 (de) Nicht-radioaktives strontiummittel zur behandlung von krebs
ATE545421T1 (de) Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat
ATE406868T1 (de) Verwendung einer zusammensetzung mit vitamin k1- oxid oder einem derivat daraus zur behandlung und/oder vorbeugung von hautverletzungen bei säugern
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties